Advertisement

Pharmacological Investigations of Cholinergic Mechanisms in Schizophrenia and Manic Psychosis

  • P. A. Berger
  • K. L. Davis
  • L. E. Hollister

Abstract

During the past twenty years the biological investigation of major emotional disorders has focused on possible disturbances of central neurotransmission. The possible roles of serotonin, norepinephrine and dopamine have been reviewed recently (Schildkraut, 1974; Shopin et al., 1974; Goodwin and Murphy, 1974; Matthysse and Lipinski, 1975; Baldessarini, 1975; Berger, 1977; Berger et al., 1978). Other recent reviews have considered the possible role of alterations in the balance between neurotransmitters (Janowsky et al., 1972b; Friedhoff and Alpert, 1973; Davis et al., 1975). This chapter will focus on the possible role of cholinergic mechanisms in the pathophysiology of schizophrenia and the affective disorders.

Keywords

Schizophrenic Patient Tardive Dyskinesia Brief Psychiatric Rate Scale Choline Chloride Corpus Striatum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anden, N.E., 1972, Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs, J. Pharm. Pharmacol 24: 905.PubMedCrossRefGoogle Scholar
  2. Anden, N.E., 1974, Effects of oxotremorine and physostigmine on the turnover of dopamine in the corpus striatum and the limbic system, J. Pharmacol 26: 138.CrossRefGoogle Scholar
  3. Aquilonius, S.M., and Eckernas, S.A., 1975, Plasma concentration of free choline in patients with Huntington’s chorea on high doses of choline chloride, N. Engl. J. Med. 293: 1105.PubMedGoogle Scholar
  4. Baldessarini, R.J., 1975, The basis for the amine hypothesis in affective disorders, Arch. Gen. Psychiatry 52: 1087.Google Scholar
  5. Bartholini, G., Stadler, H., Gadeo-Ciria, M., and Lloyd, K.G., 1976, The use of the push- pull cannula to estimate the dynamics of acetylcholine and catecholamines within various brain areas, Neuropharmacology 75: 515.CrossRefGoogle Scholar
  6. Berger, P.A., 1977, Neurotransmitters and affective disorders, in “Neurotransmitter Function” (W. Fields, ed.), pp. 305 - 335, Stratton, New York.Google Scholar
  7. Berger, P.A., Elliott, G.R., and Barchas, J.D., 1978, Neuroregulators and schizophrenia, in “Psychopharmacology: A Generation of Progress” (M. Lipton, A. Dimascio and K. Killam eds.), pp. 1071–1083, Raven Press, New York.Google Scholar
  8. Bowers, M.B., Goodman, E., and Sim, V.M., 1964, Some behavioral changes in man following anticholinesterase administration, J. Nerv. Ment. Dis. 138: 383.PubMedCrossRefGoogle Scholar
  9. Burki, H.R., Eichenberger, E., Sayers, A.C., and White, T.C., 1975, Clozapine and the dopamine hypothesis of schizophrenia: a critical appraisal, Pharmakopsychiatry 8: 115.CrossRefGoogle Scholar
  10. Carlsen, A., 1978, Antipsychotic drugs, neurotransmitters and schizophrenia, Am. J. Psychiatry 135: 164.Google Scholar
  11. Carroll, B.J., Frazer, A., Schless, A., and Mendels, J., 1973, Cholinergic reversal of manic symptoms, Lancet 7: 427.CrossRefGoogle Scholar
  12. Cohen, E.L., and Wurtman, R.J., 1975, Brain acetylcholine: increase after systematic choline administration, Life Sci. 16 (7): 109S.CrossRefGoogle Scholar
  13. Collard, J., Lecoq, R., and Demaret, A., 1965, Un essai de therapeutique pathogenique de la schizophrenic par un acetylcholinique: l’oxotremorine, Acta. Neurol Belg. 65: 122.PubMedGoogle Scholar
  14. Costall, B., and Naylor, R.J., 1976, Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine, Eur. J. Pharmacol 35: 161.PubMedCrossRefGoogle Scholar
  15. Davis, K.L., Hollister, L.E., Berger, P.A., and Barchas, J.D., 1975, A cholinergic imbalance hypothesis of psychoses and movement disorders: strategies for evaluation, Psychopharmacology Comm. 1: 533.Google Scholar
  16. Davis, K.L., Hollister, L.E., Barchas, J.D., and Berger, P.A., 1976a, Choline in tardive dyskinesia and Huntington’s disease, Life Sci. 19: 1501.CrossRefGoogle Scholar
  17. Davis, K.L., Hollister, L.E., Overall, J.A., Johnson, A., and Train, K., 1976b, Physostigmine: effects on cognition and affect in normal subjects, Psychopharmacology 51: 23.PubMedCrossRefGoogle Scholar
  18. Davis, K.L., Berger, P.A., and Hollister, L.E., 1977, Cholinergic mechanisms in tardive dyskinesia and Huntington’s chorea, in “Neurotransmitter Function” (W. Fields ed.), pp. 247–262, Stratton, New York.Google Scholar
  19. Davis, K.L., Hollister, L.E., and Tepper, J., 1978, Cholinergic inhibition of methylphenidate induced stereotypy with oxotremorine, Psychopharmacology 56: 1.PubMedCrossRefGoogle Scholar
  20. El-Yousef, M.K., Janowsky, D.S., Davis, J.M., and Rosenblatt, J.E., 1973, Induction of severe depression by physostigmine in marijuana intoxicated individuals, Br. J. Addict. 68: 321.CrossRefGoogle Scholar
  21. Feighner, J.P., Robins, R., Guze, S.B., Woodruff, R.A., Winokur G., and Munoz, R., 1972, Diagnostic criteria for use in psychiatric research, Arch. Gen. Psychiatry 26: 51.Google Scholar
  22. Friedhoff, A.J., and Alpert, M., 1973, A dopaminergic-cholinergic mechanism in production of psychotic symptoms, Biol. Psychiatry 6: 165.PubMedGoogle Scholar
  23. Fries, E.D., 1954, Mental depression in hypertensive patients treated for long periods with large doses of reserpine, N. Engl. J. Med. 251: 1006.CrossRefGoogle Scholar
  24. Fulcher, J.H., Gallagher, W.J., and Pfeiffer, C.C., 1957, Comparative lucid intervals after amobarbital, C02, and arecoline in the chronic schizophrenic, AMA Arch. Neurol Psychiatry 78: 392.Google Scholar
  25. Gautier, J., Jus, A., Villeneuve, A., Jus, K., Pires, P., and Villeneuve, R., 1977, Influence of the antiparkinsonian drugs on the plasma level of neuroleptics, Biol. Psychiatr. 12: 389.Google Scholar
  26. Gershon, S., and Shaw, F.H., 1961, Psychiatric sequelae of chronic exposure to organophosphorous insecticides, Lancet 7: 1371.CrossRefGoogle Scholar
  27. Goodwin, F.K., and Murphy, D.L., 1974, Biological factors in affective disorders and schizophrenia, in “Psychopharmacological Agents” (M. Gordon, ed.), pp. 9–37, Academic Press, New York.Google Scholar
  28. Haubrich, D.R., Wang, P.F.L., Clody, D.E., and Wedeking, P.W., 1975, Increase in rat brain acetylcholine induced by choline or deanol, Life Sci. 17(6): 915.Google Scholar
  29. Itil, T.M., Keskiner, A., and Holden, O.M.C., 1969, The use of LSD and ditran in the treatment of therapy resistant schizophrenics (symptom provocation approach), Dis. Nerv. Syst. (Suppl.) 30: 93.Google Scholar
  30. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1972a, Cholinergic antagonism of methylphenidate-induced stereotyped behavior, Psychopharmacologia 27: 295.CrossRefGoogle Scholar
  31. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1972b, A cholinergic hypothesis of mania and depression, Lancet 77: 632.CrossRefGoogle Scholar
  32. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1973a, Antagonistic effects of physostigmine and methylphenidate in man, Am. J. Psychiatry 130: 1310.Google Scholar
  33. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1973b, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry 28: 542.PubMedGoogle Scholar
  34. Klawans, H.L., 1970, A pharmacological analysis of Huntington’s chorea, Tsar. Neurol. 4: 148.Google Scholar
  35. Klawans, H.L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 37: 941.PubMedCrossRefGoogle Scholar
  36. Klawans, H.L., Rubovits, R., Patel, B.C., and Weiner, W.J., 1972, Cholinergic and anti-cholinergic influences on amphetamine-induced stereotyped behavior, J. Neurol. Sci. 77: 303.CrossRefGoogle Scholar
  37. Lindvall, O., Bjorklund, A., and Moore, R.Y., 1974, Mesencephalic dopamine neurons projecting to neocortex, Brain Res. 81: 325.PubMedCrossRefGoogle Scholar
  38. Matthysse, S., and Lipinski, J., 1975, Biochemical aspects of schizophrenia, Annu. Rev. Med. 26: 551.PubMedCrossRefGoogle Scholar
  39. McKenzie, G.M., 1972, Role of the tuberculum olfactorium in stereotyped behavior induced by apomorphine in the rat.Psychopharmacologia 23: 212.PubMedCrossRefGoogle Scholar
  40. Modestin, J., Hunger, J., and Schwartz, R.B., 1973a, Uber die depressogene Wirkung von physostigmin, Arch. Psychiatry Nervenkr. 218: 61.Google Scholar
  41. Modestin, J., Schwartz, R.B., and Hunger, J., 1973b, Zur Frage beeinflussung schizophrener Symptome durch physostigmin, Pharmakopsychiatrie Neuropsychopharmakol 6: 300.Google Scholar
  42. Naylor, R.J., and Olley, J.E., 1972, Modification of the behavioral changes induced by amphetamine in the rat by lesions in the caudate nucleus, the caudate putamen and globus pallidus, Neuropharmacology 11: 91.PubMedCrossRefGoogle Scholar
  43. Overall, J.E., 1974, The brief psychiatric rating scale in psychopharmacology research, in “Psychological Measurements In Modern Psychopharmacology: Mod. Probl. Pharmacopsychiat. Vol 7” (P. Pichot, ed.), pp. 67–78, Karger, Basel.Google Scholar
  44. Petterson, U., Fyro, O.G., and Sedvall, G., 1973, A new scale for the longitudinal rating of manic states, A eta. Psychiatr. Scand. 49: 248.CrossRefGoogle Scholar
  45. Pfeiffer, C.C., and Jenny, E.H., 1957, The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain, Ann. N. Y. Acad. Sci. 66: 153.Google Scholar
  46. Pijenenburg, A.J.J., Honig, W.M.M., and Van Rossum, J.M., 1975, Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialimide-pretreated rats, Psychopharmacologia 41: 114.Google Scholar
  47. Pijnenburg, A.J.J., Honig, W.M.M., and Van der Heyden, J.A.M., 1976, Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity, Eur. J. Pharmacol 35: 45.PubMedCrossRefGoogle Scholar
  48. Randrup, A., and Munkvad, I., 1974, Pharmacology and physiology of stereotyped behavior,. Psychiatr. Res. 11: 1.CrossRefGoogle Scholar
  49. Rivera-Calimlin, L., Castaneda, L., and Lasagna, L., 1973, Effects of mode of management on plasma chlorpromazine in psychiatric patients,Clin. Pharmacol. Ther. 14: 978.Google Scholar
  50. Rosenthal, R., and Bigelow, L.G., 1973, The effects of physostigmine in phenothiazine resistant chronic schizophrenic patients: preliminary observations, Compr. Psychiatry 14: 489.PubMedCrossRefGoogle Scholar
  51. Rowntree, D.W., Nevin, S., and Wilson, 1957, The effects of diisopropylfluorophosphonate in schizophrenic and manic depressive psychosis, J. Neuro. Neurosurg. Psychiatry 78: 392.Google Scholar
  52. Schildkraut, J.J., 1974, Biogenic amines and affective disorders, Rev. Med. 25: 333.CrossRefGoogle Scholar
  53. Shopsin, B., Wilk, S., Sathananthan, G., Gershon, S., and Davis,K.L., 1974, Catecholamines and affective disorders revised: a critical assessment, J. Nerv. Ment. Dis. 158: 369.PubMedCrossRefGoogle Scholar
  54. Singh, M.M., and Smith, J.M., 1973, Reversal of some therapeutic effects of an anti-psychotic agent by an antiparkinsonism drug, J. Nerv. Ment. Dis. 757: 50.Google Scholar
  55. Singh, M.M., and Kay, S.R., 1975a, Therapeutic reversal with benztropine in schizophrenics, J Nerv. Ment. Dis. 160: 258.PubMedCrossRefGoogle Scholar
  56. Singh, M.M., and Kay,S.R., 1975b, Acomparitive study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics, Psychopharmacologia 43: 103.PubMedCrossRefGoogle Scholar
  57. Singh, M.M., and Kay, S.R., 1975c, A longitudinal comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Non-therapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences, Psychopharmacologia 43: 115.PubMedCrossRefGoogle Scholar
  58. Snyder, S.H., and Yamamura, H.I., 1977, Antidepressants and the muscarinic acetylcholine receptor, Arch. Gen. Psychiatry 34: 236.PubMedGoogle Scholar
  59. Snyder, S.H., Greenburg, D., and Yamamura, H.I., 1974, Antischizophrenic drugs and brain cholinergic receptors, Arch. Gen. Psychiatry 31: 58.PubMedGoogle Scholar
  60. Stevens, J.R., 1973, An anatomy of schizophrenia? Arch. Gen. Psychiatry 29: 111.Google Scholar
  61. Tamminga, C., Smith, R.C., Chang, S., Harvuszti, J.S., and Davis, J.M., 1976, Depression associated with oral choline, Lancet II: 905.CrossRefGoogle Scholar
  62. Ungerstedt, U., 1971, Stereotoxic mapping of the monoamine pathways in the rat brain, Acta Physiol. Scand. (Suppl.) 367: 1.Google Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • P. A. Berger
    • 1
    • 2
  • K. L. Davis
    • 1
    • 2
  • L. E. Hollister
    • 1
    • 2
  1. 1.Veterans Administration HospitalPalo AltoUSA
  2. 2.Department of Psychiatry and Behavioral SciencesStanford University School of MedicineStanfordUSA

Personalised recommendations